Annovis Bio, Inc.
Moat Score — Annovis Bio, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Buntanetap's multi-target translational inhibition mechanism is patent-protected and scientifically distinct from the single-target antibody approaches dominating Alzheimer's drug development, though as a single-asset company Annovis's overall IP estate is narrow. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small clinical-stage company with no commercial manufacturing scale, Annovis has no cost advantage versus large pharma competitors like Biogen/Eisai or Eli Lilly. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | If approved, an oral disease-modifying therapy could command meaningful specialty pricing, but Annovis would face direct pricing and access comparisons against the already-approved, well-reimbursed antibody class. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A small-molecule neurodegeneration therapy exhibits no network effect between users. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Neurologists and patients face relatively low switching costs between chronic neurodegenerative disease therapies, particularly since buntanetap would likely be considered as an alternative or adjunct rather than requiring a difficult treatment transition. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | Alzheimer's and Parkinson's disease are both very large markets that comfortably support multiple competing approved therapies, so efficient-scale dynamics do not meaningfully protect Annovis even if buntanetap is approved. |